EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

TNF Inhibitor‐Induced Sarcoidosis‐Like Lesions in Inflammatory Bowel Disease

Zlata Chkolnaia iD, Benedicte Lebrun-Vignes, Aurelien Amiot, Mathieu Uzzan iD, Nicolas Richard, Maeva Charkaoui, Guillaume Le Cosquer, Carmen Stefanescu, Melanie Serrero, Laurianne Plastaras, Sophie Vieujean iD, David Laharie und 1 weitere

United European Gastroenterology Journal · 2026

DOI: 10.1002/ueg2.70015 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, 2026. Verfasst von Zlata Chkolnaia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Paris Cite University, Paris, France. Hauptthemen laut MEDLINE: Sarcoidosis, Inflammatory Bowel Diseases, Tumor Necrosis Factor Inhibitors, Tumor Necrosis Factor-alpha. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While tumor necrosis factor (TNF) inhibitors can induce paradoxical reactions, sarcoidosis‐like disease has hardly been reported so far. This study aimed to describe the epidemiological, diagnostic and therapeutic features of TNF inhibitor‐induced sarcoidosis‐like lesions in patients with inflammatory bowel disease.

Methods

We conducted a case series across 59 institutions affiliated with the Groupe d’Etude Therapeutique des Affections Inflammatoires du Tube Digestif . Diagnosis of TNF inhibitor‐induced sarcoidosis was based on typical clinical and radiological signs, histological evidence of non‐necrotizing granuloma, exclusion of alternative diagnoses, and a timeline consistent with drug exposure. A pharmacovigilance expert reviewed each case to confirm drug causality.

Results

We identified 14 cases of sarcoidosis‐like lesions, including 9 patients with Crohn's disease, 4 ulcerative colitis, and 1 with unclassified inflammatory bowel disease. The implicated medications were infliximab (8), adalimumab (5), and golimumab (1), predominantly in first‐time biotherapy users (71%). The median time from treatment initiation to sarcoidosis diagnosis was 27.5 months (range 3–91). Common clinical manifestations included dyspnea (71%), coughing (50%) and fever (50%). Ten patients discontinued TNF inhibitor therapy and started oral steroids, leading to complete symptom resolution in seven cases and improvement in two. Median time from steroid initiation to clinical remission of sarcoidosis was 84 days (range 11–134). After a median follow‐up of 40 months, while no relapses occurred in 13 patients, one showed persistent sarcoidosis activity.

Conclusions

TNF inhibitor‐induced sarcoidosis should be considered in inflammatory bowel disease patients with chronic respiratory symptoms or fever after exclusion of mycobacterial infection. Management involves discontinuation of TNF inhibitors and a course of steroids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcoidosisInflammatory Bowel DiseasesTumor Necrosis Factor InhibitorsTumor Necrosis Factor-alphaHumansFemaleMaleAdultMiddle AgedInfliximabAdalimumabAgedAntibodies, MonoclonalRetrospective StudiesCrohn DiseaseYoung Adult

Stichwörter der Autor:innen

Crohn's diseaseTNF inhibitorscorticosteroid treatmentinflammatory bowel diseasesarcoidosis‐like lesionsulcerative colitis

Substanzen

InfliximabAdalimumabTumor Necrosis Factor InhibitorsTumor Necrosis Factor-alphaAntibodies, Monoclonalgolimumab

Autor:innen und Institutionen

  • Paris Cite University, Paris, France.
  • Regional Pharmacovigilance Centre, Department of Medical Pharmacology, Pitié-Salpêtrière Hospital, APHP.Sorbonne Université, Paris, France.
  • Department of Gastroenterology, University Hospital of Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, Inserm, CESP, Le Kremlin Bicêtre, France.
  • Gastroenterology Department, Paris Est Créteil University UPEC, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for ImmUne disordErs, Crét…
  • Department of Gastroenterology, University Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-gut-brain Axis", CHU Rouen, Rouen, France.
  • Department of Hepatogastroenterology, Dijon University Hospital, Dijon, France.

ORCID-Profile: Zlata Chkolnaia, Mathieu Uzzan, Sophie Vieujean

Zitieren

APA

Chkolnaia, Z., Lebrun-Vignes, B., Amiot, A., Uzzan, M., Richard, N., Charkaoui, M., Le Cosquer, G., Stefanescu, C., Serrero, M., Plastaras, L., Vieujean, S., Laharie, D., & Seksik, P. (2026). TNF Inhibitor‐Induced Sarcoidosis‐Like Lesions in Inflammatory Bowel Disease. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70015

Vancouver

Chkolnaia Z, Lebrun-Vignes B, Amiot A, Uzzan M, Richard N, Charkaoui M, et al. TNF Inhibitor‐Induced Sarcoidosis‐Like Lesions in Inflammatory Bowel Disease. United European Gastroenterology Journal. 2026. doi:10.1002/ueg2.70015

BibTeX
@article{Chkolnaia2026,
  author = {Chkolnaia, Zlata and Lebrun-Vignes, Benedicte and Amiot, Aurelien and Uzzan, Mathieu and Richard, Nicolas and Charkaoui, Maeva and Le Cosquer, Guillaume and Stefanescu, Carmen and Serrero, Melanie and Plastaras, Laurianne and Vieujean, Sophie and Laharie, David and Seksik, Philippe},
  title = {TNF Inhibitor‐Induced Sarcoidosis‐Like Lesions in Inflammatory Bowel Disease},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  doi = {10.1002/ueg2.70015}
}
Kostenlos starten →